Quarterly ResultAug 4, 2026, 04:08 PM
OnKure Q2 Net Loss $15.3M; $176M Cash Funds Operations into 2029
AI Summary
OnKure Therapeutics reported its second quarter 2026 financial results, showing a net loss of $15.3 million, or $0.31 per share. The company maintained a strong financial position with $176.4 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2029. OnKure also provided positive updates on its pipeline, with IND submissions for its next-generation PI3Kα pan-mutant selective candidates, OKI-345 and OKI-355, on track for the first half of 2027.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $176.4 million as of June 30, 2026.
- Company expects current cash to fund operations into 2029.
- Net loss for Q2 2026 was $15.3 million, compared to $15.4 million for Q2 2025.
- Net loss per share was $0.31 for Q2 2026, down from $1.14 for Q2 2025.
- Research and development expenses were $12.6 million for Q2 2026, consistent with Q2 2025.
- General and administrative expenses increased to $4.3 million for Q2 2026 from $3.7 million for Q2 2025.
- IND submissions for OKI-345 (breast cancer) and OKI-355 (vascular anomalies) are planned for 1H 2027.
Price Impact
More from OKUR